THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES

Summary

Principal Investigator: Oliver W Press
Abstract: DESCRIPTION (provided by applicant): The overall objective of this Program Project Grant is to improve the outcome of patients with hematologic malignancies by developing curative strategies using radiolabeled monoclonal antibodies (RAb) in the setting of hematopoietic cell transplantation (HCT). Our prior studies have established the feasibility, safety and anti-tumor efficacy of this approach. We now propose to improve, refine and extend this treatment for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and lymphomas by targeting radionuclides to neoplastic cells using monoclonal antibodies (Ab) directed at the CD45 antigen present on the surface of these malignancies. We will pursue this global objective in three highly interactive, complementary projects. In Project 1 (Leukemia), we will conduct a Phase II study of 131l-labeled anti-CD45 antibody (BC8) in conjunction with fludarabine (FLU), 2 Gy total body irradiation (TBI) and allogeneic HCT in patients with AML in remission (Aim 1), extend the approach to patients lacking histocompatibility locus antigen (HLA)-matched donors by investigating 131l-BCS in the setting of haplo-identical transplantation for AML, ALL and MDS (Aim 2) and explore the use of 90Yttrium-BC8, FLU, and 2 Gy TBI in a Phase I dose-finding study conducted at our center and at the City of Hope Medical Center for AML, ALL and MDS (Aim 3). In Project 2 (Lymphoma), we will define the optimal BCS protein dose for targeting CD45 in patients with B and T cell lymphomas (Aim 1), compare and contrast targeting of lymphoma cells with radiolabeled anti-CD20 and anti-CD45 RAb (Aim 2), compare the relative merits of 111ln-BC8 and 86Y-BC8 for conducting trace-labeled biodistribution studies and dosimetry (Aim 3), and estimate the maximally tolerated dose of 90Y-labeled BCS Ab that can be administered safely to lymphoma patients in a Phase I dose-escalation trial (Aim 4). In Project 3 (Pretargeting Trials), we plan to conduct the "first in human" clinical trials of multi-step pretargeted radioimmunotherapy directed at the CD45 antigen in patients with leukemia (Aim 1) and lymphoma (Aim 2). In addition, we will compare the biodistributions of radioactivity in tumor sites and in normal organs following targeting with directly radiolabeled 111ln-BC8 antibody or with pretargeted BC8-streptavidin followed by 111In-DOTA-biotin. We predict that these comparative biodistribution studies will confirm our hypothesis that pretargeted radioimmunotherapy (PRIT) will deliver much more radioactivity to tumor cells and much less radioactivity to normal tissues than is possible with conventional radioimmunotherapy (RIT). We anticipate that the investigations described in this application will allow us to maximize the therapeutic efficacy and minimize the toxicity of myeloablative RIT for hematologic malignancies.
Funding Period: 1997-05-01 - 2016-07-31
more information: NIH RePORT

Top Publications

  1. pmc Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome
    Raya Mawad
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington
    Biol Blood Marrow Transplant 20:1363-8. 2014
  2. pmc Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
    Robert Chen
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA
    Blood 119:6379-81. 2012
  3. pmc Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Clin Cancer Res 17:7373-82. 2011
  4. pmc Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
    Lihua E Budde
    825 Eastlake Ave E, G3 200, Seattle, WA, USA
    J Clin Oncol 29:3023-9. 2011
  5. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
  6. pmc Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Blood 116:4231-9. 2010
  7. pmc Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
    D Scott Wilbur
    Department of Radiation Oncology, University of Washington, Seattle, Washington 98105, USA
    Bioconjug Chem 21:1225-38. 2010
  8. pmc Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium
    Ajay K Gopal
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leuk Lymphoma 51:1523-9. 2010
  9. pmc Pretargeted radioimmunotherapy for hematologic and other malignancies
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Biother Radiopharm 25:125-42. 2010
  10. pmc Allogeneic hematopoietic cell transplantation in mantle cell lymphoma
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Best Pract Res Clin Haematol 25:165-74. 2012

Research Grants

Detail Information

Publications45

  1. pmc Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome
    Raya Mawad
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington
    Biol Blood Marrow Transplant 20:1363-8. 2014
    ..Moreover, the arbitrary limit of 43 Gy to the marrow may be unnecessarily conservative, and continued escalation of targeted radioimmunotherapy doses may be feasible to further reduce relapse. ..
  2. pmc Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
    Robert Chen
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA
    Blood 119:6379-81. 2012
    ..8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT...
  3. pmc Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Clin Cancer Res 17:7373-82. 2011
    ..We engineered a series of SAv FPs that downmodulate the affinity of SAv for biotin, while retaining high avidity for divalent DOTA-bis-biotin to circumvent this problem...
  4. pmc Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
    Lihua E Budde
    825 Eastlake Ave E, G3 200, Seattle, WA, USA
    J Clin Oncol 29:3023-9. 2011
    ....
  5. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
    ..These data suggest that anti-CD45 PRIT using an α-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia...
  6. pmc Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Blood 116:4231-9. 2010
    ..0001). Treatment was well tolerated, with no treatment-related mortalities. This study demonstrates the favorable biodistribution profile and excellent therapeutic efficacy attainable with ²¹³Bi-labeled anti-CD20 PRIT...
  7. pmc Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
    D Scott Wilbur
    Department of Radiation Oncology, University of Washington, Seattle, Washington 98105, USA
    Bioconjug Chem 21:1225-38. 2010
    ..While the reasons for the higher blood and liver concentrations are unknown, the differences in the galactose structures of the clearance agents 1 and 2 may play a role...
  8. pmc Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium
    Ajay K Gopal
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leuk Lymphoma 51:1523-9. 2010
    ..5%) and grade 4 non-hematologic adverse events (n = 2) were rare, with no treatment-related deaths. GCD(R) is a safe and effective outpatient regimen for relapsed lymphoma, and successfully mobilizes PBSCs...
  9. pmc Pretargeted radioimmunotherapy for hematologic and other malignancies
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Biother Radiopharm 25:125-42. 2010
    ..With continued research, PRIT-based treatment strategies promise to become cornerstones to improved outcomes for cancer patients despite their complexities...
  10. pmc Allogeneic hematopoietic cell transplantation in mantle cell lymphoma
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Best Pract Res Clin Haematol 25:165-74. 2012
    ....
  11. pmc 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
    Naoya Hattori
    aDepartment of Radiology, Division of Nuclear Medicine, University of Washington bFred Hutchinson Cancer Research Center, Seattle cPacific Northwest National Laboratory, Richland, Washington, USA
    Nucl Med Commun 33:1225-31. 2012
    ..To investigate radiation doses to the testes delivered by a radiolabeled anti-CD20 antibody and its effects on male sex hormone levels...
  12. pmc Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design
    Jack M Lionberger
    Saint Louis University, Saint Louis, MO, USA
    Br J Haematol 166:375-81. 2014
    ....
  13. pmc Advances in the treatment of hematologic malignancies using immunoconjugates
    Maria Corinna Palanca-Wessels
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA and
    Blood 123:2293-301. 2014
    ..These studies have yielded encouraging results particularly in lymphoma. ICs comprise an exciting group of therapeutics that promise to play an increasingly important role in the management of hematologic malignancies...
  14. pmc Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma
    Ajay K Gopal
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 20:770-5. 2014
    ..9 years). Fludarabine up to 210 mg/m(2) can be safely delivered with myeloablative (131)I-tositumomab and ASCT in older adults with B-NHL...
  15. pmc Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 19:1403-6. 2013
    ..These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT...
  16. pmc Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 121:3759-67. 2013
    ..7 K/µL 2 weeks after HSCT and recovery by 4 weeks. These data suggest that (211)At-anti-CD45 RIT in conjunction with HSCT may be a promising therapeutic option for AML...
  17. pmc Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
    Raya Mawad
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 380, Seattle, WA 98109 1024, USA
    Curr Hematol Malig Rep 8:132-40. 2013
    ..The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant...
  18. pmc A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
    Lihua E Budde
    Clinical Research Dvision, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 161:183-91. 2013
    ..High-dose vorinostat can be delivered safely with (R)ICE, achieves potentially synergistic drug levels, and warrants further study, although adequate gastrointestinal prophylaxis is warranted...
  19. pmc Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas
    M Corinna A Palanca-Wessels
    Division of Hematology, Department of Medicine, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Cancer 116:1126-33. 2010
    ..This article summarizes the current knowledge supporting the use of radioimmunotherapy, an underused but effective treatment modality in NHL patients...
  20. ncbi Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation
    Jaideep Shenoi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine from the University of Washington, Seattle, Washington, USA
    Curr Opin Oncol 22:143-9. 2010
    ....
  21. ncbi Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose
    Joseph G Rajendran
    Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 49:837-44. 2008
    ..The goal of each approach is to deliver maximal myeloablative amounts of radioactivity within the tolerance of critical normal organs...
  22. pmc Radioimmunotherapy-based conditioning regimens for stem cell transplantation
    Michelle M Zhang
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
    Semin Hematol 45:118-25. 2008
    ....
  23. pmc Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?
    William I Bensinger
    University of Washington, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 390, Seattle, WA 98109, USA
    Best Pract Res Clin Haematol 20:783-95. 2007
    ....
  24. ncbi The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
    R N Pham
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Bone Marrow Transplant 40:1039-44. 2007
    ..52, P=0.03), chemoresistance (HR=1.82, P=0.02), > or =2 prior therapies (HR=1.8, P=0.03) and prior radiation (HR=1.99, P=0.003). These data suggest that the histologic grade of FL does not impact PFS or relapse following HDT and ASCT...
  25. ncbi The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation
    Grant E Keeney
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
    Leuk Lymphoma 48:1961-7. 2007
    ..82, p = 0.03) after adjusting for FLIPI. These data suggest that the FLIPI and select non-FLIPI factors after adjustment for the FLIPI are associated with survival in FL patients undergoing ASCT...
  26. ncbi Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies
    Steven I Park
    Department of Medicine, Division of Hematology, University of Washington, USA
    Curr Opin Hematol 14:632-8. 2007
    ..This review will present the latest information on radioimmunotherapy for treatment of hematologic malignancies in various clinical settings and assess its long-term safety profile...
  27. ncbi High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98195, USA
    J Clin Oncol 25:1396-402. 2007
    ..Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy...
  28. pmc Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
    Anastasia Pantelias
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Blood 109:4980-7. 2007
    ..This study highlights the importance of screening the antigenic expression on lymphomas to select the optimal reagent for PRIT...
  29. ncbi A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies
    Yukang Lin
    The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cancer Res 66:3884-92. 2006
    ..These promising results have prompted large-scale cGMP production of the BC8 fusion protein for clinical trials to be conducted in patients with hematologic malignancies...
  30. pmc Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
    Brian G Till
    Clinical Research Division of Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 49:1062-73. 2008
    ....
  31. ncbi Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies
    Eneida R Nemecek
    Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
    Cancer Biother Radiopharm 23:181-91. 2008
    ..We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model...
  32. pmc Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
    ..These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma...
  33. pmc 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma
    Ajay K Gopal
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, USA
    Blood 113:5905-10. 2009
    ..5 days, P < .001) compared with controls. These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients...
  34. pmc A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
    Robert M Sharkey
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Blood 113:3891-5. 2009
    ..This perspective discusses how these issues could affect current and future clinical trials...
  35. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009
    ..We hypothesize that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of survival for patients with relapsed lymphomas compared with currently available treatment strategies...
  36. pmc Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia
    John M Pagel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Cancer Res 69:185-92. 2009
    ..These data suggest that pretargeted methods for delivering RIT may be superior to conventional RIT when targeting CD45 for the treatment of leukemia and may allow for the intensification of therapy, while minimizing toxicities...
  37. pmc High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Cancer 113:1344-50. 2008
    ..We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients...
  38. ncbi Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma
    Franz Buchegger
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Oncologist 13:657-67. 2008
    ....
  39. pmc Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA
    Blood 112:830-5. 2008
    ....
  40. pmc 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center D5 380, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109, USA
    Blood 107:2184-91. 2006
    ..39-1.08; P = .09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and phase 2 results are sufficiently encouraging to warrant further study...

Research Grants30

  1. NK Cells, Their Receptors and Unrelated Donor Transplant
    Jeffrey S Miller; Fiscal Year: 2013
    ..The program also promises to change practice of allogeneic transplantation, to the greater benefit of patients with advanced leukemia. ..
  2. Novel Approaches to Stem Cell Transplantation
    Nelson J Chao; Fiscal Year: 2013
    ..Our commitment to patients'welfare and improved outcomes continues to drive our efforts. The lessons learned from these studies will also be applicable to other forms of allogeneic hematopoietic cell transplantation. ..
  3. Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia
    Carlo M Croce; Fiscal Year: 2013
    ..abstract_text> ..
  4. Characterization of Pathways Controlling Cancer at the Level of Gene Regulation
    Phillip A Sharp; Fiscal Year: 2013
    ..The interactions and involvement of Rb and miRNAs in induction of cell death following DNA damage will also be studied. ..
  5. CSHL CANCER CENTER SUPPORT GRANT
    BRUCE W STILLMAN; Fiscal Year: 2013
    ....
  6. UNMC EPPLEY CANCER CENTER SUPPORT GRANT
    Kenneth H Cowan; Fiscal Year: 2013
    ....